PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans
Autor: | Anna Cabrelle, Alberto Ferlin, Nicola Caretta, Andrea Garolla, Giorgio Palù, Marco Ferigo, Carlo Foresta, A Lana |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2005 |
Předmět: |
Adult
Male medicine.medical_specialty Endothelium Phosphodiesterase Inhibitors Urology Piperazines Neovascularization Vardenafil Dihydrochloride 3' 5'-Cyclic-GMP Phosphodiesterases Internal medicine medicine Humans Sulfones Progenitor cell Interleukin 3 Cyclic Nucleotide Phosphodiesterases Type 5 business.industry Triazines Imidazoles Flow Cytometry Hematopoietic Stem Cells Hematopoietic Stem Cell Mobilization Endothelial stem cell Haematopoiesis medicine.anatomical_structure Endocrinology Cancer research Bone marrow Endothelium Vascular medicine.symptom Stem cell business |
Popis: | Bone marrow-derived endothelial progenitor cells (EPCs) originate from haematopoietic stem cells in bone marrow and migrate into the peripheral circulation to promote endothelial repair and neovascularization. The number of circulating progenitor cells is reduced in patients with cardiovascular risk factor. The aim of our study was to determine the number of these cells in healthy patients and to evaluate the effect of Vardenfil, a phosphodiesterases-5 (PDE-5) inhibitor, in the number of circulating EPCs. In our study, we found a significant increase in the number of these cells after the drug administration. |
Databáze: | OpenAIRE |
Externí odkaz: |